Related Experiment Video
Updated: May 17, 2025
09:55
Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
Published on: October 4, 2024
283
[New Investment for Theranostics in Europe].
Kaori Nomura1, Kohshin Washiyama1, Noboru Oriuchi1
1Advanced Clinical Research Center, Fukushima Global Medical Science Center, Fukushima Medical University.
Kaku Igaku. the Japanese Journal of Nuclear Medicine
|April 2, 2025
Summary
Japan is increasing its focus on radioactive isotope (RI) medical applications, mirroring European advancements in theranostics. However, Japan needs greater industry collaboration and funding to advance RI drug development and clinical applications.
Area of Science:
- Nuclear Medicine
- Radiopharmaceutical Development
- Theranostics
Background:
- Japan's government prioritizes radioactive isotope (RI) medical applications, with initiatives like F-REI launching RI-based drug development.
- Europe has initiated three major theranostics projects with significant public-private funding (60 million euros) under Horizon Europe.
- These European projects, including Thera4Care, Accelerate.EU, and ILLUMINATE, focus on advancing RI drug discovery and clinical applications.
Purpose of the Study:
- To analyze the current landscape of RI-based theranostics development in Japan and Europe.
- To identify key differences in research initiatives, industry participation, and funding mechanisms.
- To highlight areas for improvement in Japan to foster clinical applications and international collaboration.
Main Methods:
- Comparative analysis of government policies and research initiatives in Japan and Europe.
- Review of European theranostics projects (Thera4Care, Accelerate.EU, ILLUMINATE) and their objectives.
- Assessment of industry engagement and financial contribution models in RI drug development.
Main Results:
- Japan shows government support for RI medical use but lacks robust industry involvement compared to Europe's public-private partnerships.
- European projects are advancing targeted therapies, such as astatine-211 (211At) and lutetium-177 (177Lu)-based treatments, with defined clinical trial timelines.
- Significant European investment (€60 million) is driving theranostics innovation through initiatives like the Innovative Health Initiative (IHI).
Conclusions:
- Advancing theranostics in Japan requires enhanced industry engagement, knowledge sharing, and workforce training.
- Bridging the gap in industry participation and funding is crucial for Japan to realize the full potential of RI-based therapies.
- Fostering joint research and international collaboration will accelerate the clinical translation of radiopharmaceuticals in Japan.
Related Concept Videos
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
01:29Positron Emission Tomography
3.9K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
3.9K